Boston, MANCT07357519Now EnrollingIRB Ready

Relapsed / Refractory Osteosarcoma Clinical Trial in Boston, MA

Access cutting-edge relapsed / refractory osteosarcoma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Lantheus Medical Imaging

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access relapsed / refractory osteosarcoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed / refractory osteosarcoma treatment provided free

Apply for This Boston Location

Check if you qualify for this relapsed / refractory osteosarcoma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Relapsed / Refractory Osteosarcoma Study in Boston

This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.

Sponsor: Lantheus Medical Imaging

Who Can Participate

Inclusion Criteria

Participants must meet all the following criteria to be enrolled in the study
Histopathologic documented diagnosis of R/R osteosarcoma
Must have disease characterized by at least one of the following (Participants meeting only (b.), only (c.), or only (b. and c.) must be discussed with and receive written approval from the Sponsor to qualify).
Measurable as defined in RECIST 1.1
Evaluable non-measurable disease as per RECIST 1.1
Bone only without a soft tissue component: must be 18F-FDG-PET avid and evaluable by serial 18F-FDG-PET imaging studies.
Age: a. First Cohort in Phase 1: ≥ 18 years-of-age at the time of signature of the main study ICF. b. Second and subsequent cohorts, in Phase 1 and all participants in Phase 2: ≥12years-of-age at the time of signature of the main ICF.
Performance Status:
Eastern Cooperative Oncology Group (ECOG) Performance Score (PS): 0 - 2
Lansky PS ≥ 50.
Body weight: ≥ 30 kg.
Tumor biopsies; Fresh or Archival
Progression following at least one course of chemotherapy, which includes neoadjuvant / perioperative systemic therapy.
All adverse events (AEs) related to prior therapies (chemotherapy / systemic therapies, radiation, surgery) must have resolved to Grade 1 or baseline
Organ Function
Pregnancy Women of Child-Bearing Potential (WOCBP) must have a negative serum pregnancy test result at screening
Contraception- Male participants with a WOCBP partner must use 2 forms of acceptable contraception
Written informed consent and/or assent must be obtained according to local guidelines and signed and dated by the participant, parent, and/or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses

Exclusion Criteria

Participants meeting any of the following criteria will be excluded from the study
Known allergies, hypersensitivity, or intolerance to LNTH-2403 and/or its excipients
Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the participant's safety, compliance with the study, or otherwise impair the assessment of study results
Concurrent treatment with any other anti-neoplastic agents, including localized radiation therapy
Known active infection
Participation in an interventional study of another investigational agent
Prior therapies or diagnostics
Active prior or concurrent malignancy: immunoglobulin),
Known active liver disease from any cause, Hepatitis A Virus
Known to be human immunodeficiency virus (HIV) positive
Clinically relevant cardiovascular disease
Receipt of live vaccine within the 30 days prior to the first dose o
A female participant who is pregnant or breastfeeding
Major surgical procedure within 28 days of the first dose of LNTH-2403.
Participant is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07357519) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed / Refractory Osteosarcoma Treatment Options in Boston, MA

If you're searching for relapsed / refractory osteosarcoma treatment options in Boston, MA, this clinical trial (NCT07357519) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed / refractory osteosarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed / refractory osteosarcoma clinical trials near you to find additional studies recruiting in your area.

More Sarcoma Trials in Boston, MA

See all sarcoma clinical trials recruiting in Boston — not just this study.

Browse Sarcoma Trials in Boston →

Browse More Trials by Condition

Sarcoma TrialsRheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsSleep Apnea TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA